Engineering a Near-Infrared Spiro-Based Aggregation-Induced Emission Luminogen for DNAzyme-Sensitized Photothermal Therapy with High Efficiency and Accuracy
Aggregation-induced emission luminogen (AIEgens)-based photothermal therapy (PTT) has grown into a sparkling frontier for tumor ablation. However, challenges remain due to the uncoordinated photoluminescence (PL) and photothermal properties of classical AIEgens, along with hyperthermia-induced antiapoptotic responses in tumor cells, hindering satisfactory therapeutic outcomes. Herein, a near-infrared (NIR) spiro-AIEgen <b>TTQ-SA</b> was designed for boosted PTT by auxiliary DNAzyme-regulated tumor cell sensitization. <b>TTQ-SA</b> with a unique molecular structure and packing mode was initially fabricated, endowing it with a strong AIE effect, favorable PL quantum yield, and good photothermal performance. DNAzyme, as a gene silencing tool, could alleviate antiapoptosis response during PTT. By integrating <b>TTQ-SA</b> and DNAzyme into folate-modified poly(lactic-<i>co</i>-glycolic acid) (PLGA) polymer, the as-fabricated nanosystem could promote cell apoptosis and sensitize tumor cells to PTT, thereby maximizing the therapeutic outcomes. With the combination of spiro-AIEgen-based PTT and DNAzyme-based gene silencing, the as-designed nanosystem showed promising NIR and photothermal imaging abilities for tumor targeting and demonstrated significant cell apoptotic, antitumor, and antimetastasis effects against orthotopic breast cancer. Furthermore, a synergistic antitumor effect was realized in spontaneous MMTV-PyMT transgenic mice. These findings offer new insights into AIEgen-based photothermal theranostics and DNAzyme-regulated tumor cell sensitization, paving the way for synergistic gene silencing-PTT nanoplatforms in clinical research.
Authors
- Xinwen Ou (ORCID: https://orcid.org/0000-0001-6694-7932)
- Ryan T. K. Kwok (ORCID: https://orcid.org/0000-0002-6866-3877)
- Jianwei Sun (ORCID: https://orcid.org/0000-0002-2470-1077)
- Yuqian Jiang (ORCID: https://orcid.org/0000-0002-7013-4704)
- Wei Zhao (ORCID: https://orcid.org/0000-0001-8941-3044)
- Fuan Wang (ORCID: https://orcid.org/0000-0002-3063-2485)
- Jacky W. Y. Lam
- Fan‐Cheng Kong (ORCID: https://orcid.org/0000-0001-6209-2578)
- Philip C. Y. Chow (ORCID: https://orcid.org/0000-0002-2373-503X)
- Diwei Zheng (ORCID: https://orcid.org/0000-0001-8888-9630)
- Ben Zhong Tang (ORCID: https://orcid.org/0000-0002-0293-964X)
- Yingying Chen (ORCID: https://orcid.org/0000-0003-4054-884X)
- Shengyi Yang (ORCID: https://orcid.org/0000-0002-7473-0917)
- Wenqian Yu
- Hui Wang (ORCID: https://orcid.org/0009-0003-8057-4644)
- Yifei Wang (ORCID: https://orcid.org/0009-0001-2961-9996)
Institutions
- Shenzhen Institute of Information Technology (CN)
- Hong Kong University of Science and Technology (HK)
- Wuhan University (CN)
- Chinese University of Hong Kong, Shenzhen (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Zhujiang Hospital (CN)
- Institute of Process Engineering (CN)
- Southern Medical University (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Journal of the American Chemical Society
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1021/jacs.4c14818
- Citations
- 28
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 5.16
Funders
- National Natural Science Foundation of China
- Research Grants Council, University Grants Committee
- Innovation and Technology Commission
- Environment and Conservation Fund
- Science, Technology and Innovation Commission of Shenzhen Municipality
- University Research Committee, University of Hong Kong